In order to promote the construction and development of tumor immunotherapy in Sichuan and Hubei, and improve the clinical research level of physicians in Sichuan and Hubei, Chengdu High-tech Medical Association held the "Seminar on New Advances in Cancer Treatment in Sichuan and Hubei" on December 17, 2021.

The meeting invited Professor Ma Fang from Hubei Provincial People's Hospital and Professor Peng Min from the Second Xiangya Hospital of Central South University to give opening speeches and a summary of the conference. Prof. Zhao Jing from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology focused on sharing "2021 WCLC ESMO CSCO NSCLC Targeting and Anti-vascular Therapy New Progress"; Prof. Shi Lei from Hubei University People's Hospital focused on explaining "Recombinant Human Vascular Endostatin Dosage Exploration" Optimization and Thinking"; Prof. Zhang Yan from Changde First People's Hospital, Prof. Liu Xiang from the Second Affiliated Hospital of South China University, Prof. Chen Yong from Shaoyang Central Hospital and others had a warm and in-depth discussion with all the experts based on the content of the experts' teaching .

This conference provides a platform for clinical doctors and scientific researchers to exchange diagnosis and treatment technology and academic research results, which is conducive to academic discussions and exchanges of classic cases and cutting-edge technologies in the promotion of tumor immunity, and establishes comprehensive and standardized treatment of oncology medicine. concept. It is of great significance to promote high-quality clinical research in the field of medical oncology and promote the level of clinical scientific research.